Page last updated: 2024-12-11

macrolactin a

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

macrolactin A: a 24-membered macrolide; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID10949443
CHEMBL ID491349
SCHEMBL ID359081
MeSH IDM0422908

Synonyms (4)

Synonym
macrolactin a
CHEMBL491349
SCHEMBL359081
(3z,5e,8s,9e,11z,14s,16r,17e,19e,24r)-8,14,16-trihydroxy-24-methyl-1-oxacyclotetracosa-3,5,9,11,17,19-hexaen-2-one

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
"  The pharmacokinetic profiles of both MA and SMA were much improved (greater AUC and F values) following intraperitoneal administration than following oral administration due to avoidance of acidic degradation and/or gastrointestinal first-pass extraction."( Pharmacokinetics of macrolactin A and 7-O-succinyl macrolactin A in mice.
Jung, JW; Kang, HE; Kim, DH; Kim, JM; Kwon, MH, 2014
)
0.4

Compound-Compound Interactions

ExcerptReferenceRelevance
" On the basis of an in vitro-in vivo extrapolation, our data strongly suggested that MA and SMA are unlikely to cause clinically significant drug-drug interactions mediated via inhibition or induction of most of the CYPs involved in drug metabolism in vivo, except for the inhibition of CYP2C9 by MA."( Metabolic drug-drug interaction potential of macrolactin A and 7-O-succinyl macrolactin A assessed by evaluating cytochrome P450 inhibition and induction and UDP-glucuronosyltransferase inhibition in vitro.
Bae, SH; Bae, SK; Kang, JS; Kim, CG; Kim, D; Kim, DH; Kwon, MJ; Oh, E; Park, JB, 2014
)
0.4

Bioavailability

ExcerptReferenceRelevance
"  Both MA and SMA had an extremely low oral extent of absolute bioavailability (F)."( Pharmacokinetics of macrolactin A and 7-O-succinyl macrolactin A in mice.
Jung, JW; Kang, HE; Kim, DH; Kim, JM; Kwon, MH, 2014
)
0.4
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (8)

Assay IDTitleYearJournalArticle
AID379011Cytotoxicity against mouse B16-F10 cells2006Journal of natural products, Jan, Volume: 69, Issue:1
Wortmannilactones A-D, 22-membered triene macrolides from Talaromyces wortmannii.
AID1082814Antibacterial activity against Ralstonia solanacearum race 1 assessed as growth inhibition at 50 uL at 28 degC for 3 days2012Journal of agricultural and food chemistry, Mar-28, Volume: 60, Issue:12
Production of bacillomycin- and macrolactin-type antibiotics by Bacillus amyloliquefaciens NJN-6 for suppressing soilborne plant pathogens.
AID595295Antiviral activity against Human herpesvirus 2 strain G2011Journal of natural products, Apr-25, Volume: 74, Issue:4
Non-peptide metabolites from the genus Bacillus.
AID1113124Antifungal activity against Candida albicans assessed as inhibition of mycelial growth2013Journal of agricultural and food chemistry, Apr-10, Volume: 61, Issue:14
Antimicrobial gageomacrolactins characterized from the fermentation of the marine-derived bacterium Bacillus subtilis under optimum growth conditions.
AID595294Antiviral activity against Herpes simplex virus 1 LL2011Journal of natural products, Apr-25, Volume: 74, Issue:4
Non-peptide metabolites from the genus Bacillus.
AID379012Antiviral activity against Herpes simplex virus 12006Journal of natural products, Jan, Volume: 69, Issue:1
Wortmannilactones A-D, 22-membered triene macrolides from Talaromyces wortmannii.
AID379013Antiviral activity against Herpes simplex virus 22006Journal of natural products, Jan, Volume: 69, Issue:1
Wortmannilactones A-D, 22-membered triene macrolides from Talaromyces wortmannii.
AID595293Cytotoxicity against mouse B16F10 cells2011Journal of natural products, Apr-25, Volume: 74, Issue:4
Non-peptide metabolites from the genus Bacillus.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (32)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's11 (34.38)29.6817
2010's15 (46.88)24.3611
2020's6 (18.75)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (3.13%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other31 (96.88%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]